Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009 | 0.97 | — | — | |
| SCHEMBL9339519 | 0.94 | TSHR (0.52) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL6379930 | 0.94 | TSHR (0.52) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL3793940 | 0.92 | HTT (0.56) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL6652282 | 0.92 | HTT (0.56) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL7577819 | 0.92 | TSHR (0.50) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL6654236 | 0.90 | HTT (0.60) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL1802869 | 0.89 | TSHR (0.52) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL982733 | 0.89 | — | — | |
| SCHEMBL6650487 | 0.89 | TSHR (0.52) | TSHRCYP3A4MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0543919-B1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES | SEARLE & CO (US) | 1996-04-10 | — | — | EP | claimed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | claimed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | claimed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007119600-A9 | CARBAZOLE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2008-05-02 | — | — | WO | disclosed |
| EP-0039482-B1 | PERYLENE-3,4,9,10-TETRACARBOXYLIC ACID MONOANHYDRIDE-MONOIMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-03-27 | — | — | EP | disclosed |
| EP-0090285-B1 | PIGMENT PREPARATIONS AND THEIR USE IN PIGMENTING HELIOGRAPHIC AND LAC COLOURS | BASF Aktiengesellschaft (DE) | 1985-01-16 | — | — | EP | disclosed |
| US-4490176-A | PRINTING INKS, PAINTS; PIGMENT, ALKYLBENZENE SULFONIC ACID, HYDROXYNAPHTHALENE | BASF AKTIENGESELLSCHAFT (DE) | 1984-12-25 | — | — | US | disclosed |
| EP-0076995-B1 | LIQUID STABLE PREPARATIONS AND THEIR USE | BASF Aktiengesellschaft (DE) | 1984-07-11 | — | — | EP | disclosed |
| EP-0043932-B1 | LIQUID, STABLE PREPARATIONS OF PHTHALOCYANINE PIGMENTS OR INDANTHRON AND THEIR USE | BASF Aktiengesellschaft (DE) | 1984-04-18 | — | — | EP | disclosed |
| EP-0076995-A1 | Liquid stable preparations and their use | BASF Aktiengesellschaft (DE) | 1983-04-20 | — | — | EP | disclosed |
| US-4350534-A | Fluid, stable formulations of copper phthalocyanine or indanthrone | BASF AKTIENGESELLSCHAFT (DE) | 1982-09-21 | — | — | US | disclosed |
| EP-0043932-A1 | Liquid, stable preparations of phthalocyanine pigments or indanthron and their use | BASF Aktiengesellschaft (DE) | 1982-01-20 | — | — | EP | disclosed |
| EP-0039482-A2 | Perylene-3,4,9,10-tetracarboxylic acid monoanhydride-monoimides, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | TSHR 3439/4885CYP3A4 3412/4885MEN1 4401/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | TSHR 110/4885CYP3A4 953/4885MEN1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.